Tokyo, Japan –Sep. 1, 2006 – REGiMMUNE Corporation, a privately held biopharmaceutical company, announced that it has entered into a license agreement with RIKEN. Under the agreement, an exclusive right to market/sublicense pharmaceutical products based on RIKEN’s immune regulating technology is granted to REGiMMUNE from RIKEN.

For Information Contact:
Yuko Amizaki, Director, Corporate Planning
REGiMMUNE.
+81-3-3456-0820
For conact via e-mail, please clickhere.